Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss the DMT Stroke Program on BioPub Webcast Hosted by Dr. KSS MD, PhD



Algernon Pharmaceuticals Inc. CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI discussed the Company’s DMT Stroke Clinical Research Program on BioPub webcast hosted by Dr. KSS held March 3, 2021.

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.